A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors

IF 3.4 3区 医学 Q2 HEMATOLOGY
Giancarlo Castaman , Stacy E. Croteau , Doris Quon , Lucy Lee , Letizia Polito , Víctor Jiménez-Yuste
{"title":"A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors","authors":"Giancarlo Castaman ,&nbsp;Stacy E. Croteau ,&nbsp;Doris Quon ,&nbsp;Lucy Lee ,&nbsp;Letizia Polito ,&nbsp;Víctor Jiménez-Yuste","doi":"10.1016/j.rpth.2025.102693","DOIUrl":null,"url":null,"abstract":"<div><div>People with hemophilia A have a total or partial deficiency of factor (F)VIII, causing spontaneous and/or traumatic bleeding into the joints, muscles, and soft tissues. Major surgery may be required to restore joint mobility or treat the symptoms of common comorbidities in people with hemophilia A. Additional factor replacement is recommended during the perioperative period; collated information on the experience of emicizumab-treated people with hemophilia A during major surgery is currently lacking. To provide a consolidated narrative summary of the experience with emicizumab in people with hemophilia A without FVIII inhibitors undergoing major surgery, a comprehensive literature search was performed using PubMed/MEDLINE (cut-off date: March 31, 2024); the abstract books for applicable congresses (2016–2024) were searched manually. Studies were included if reporting original data on people with hemophilia A of all ages and hemophilia A severities without FVIII inhibitors on emicizumab prophylaxis who had undergone major surgery. Outcomes collected included perioperative surgical management, adverse events, and bleeding events. Twenty publications were included; 72 procedures were reported. Twenty-two orthopedic and 34 other major procedures were specifically described. FVIII replacement was used to manage 66 procedures perioperatively, and 25 procedures were managed in conjunction with antifibrinolytics. Fifteen procedures resulted in a bleeding event, and one individual experienced a thrombotic event. No deaths were reported. This review provides a consolidated narrative of the currently reported experiences of emicizumab-treated people with hemophilia A without FVIII inhibitors undergoing major surgery, helping to support the future management decisions of emicizumab-treated people with hemophilia A during surgery.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102693"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037925000172","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

People with hemophilia A have a total or partial deficiency of factor (F)VIII, causing spontaneous and/or traumatic bleeding into the joints, muscles, and soft tissues. Major surgery may be required to restore joint mobility or treat the symptoms of common comorbidities in people with hemophilia A. Additional factor replacement is recommended during the perioperative period; collated information on the experience of emicizumab-treated people with hemophilia A during major surgery is currently lacking. To provide a consolidated narrative summary of the experience with emicizumab in people with hemophilia A without FVIII inhibitors undergoing major surgery, a comprehensive literature search was performed using PubMed/MEDLINE (cut-off date: March 31, 2024); the abstract books for applicable congresses (2016–2024) were searched manually. Studies were included if reporting original data on people with hemophilia A of all ages and hemophilia A severities without FVIII inhibitors on emicizumab prophylaxis who had undergone major surgery. Outcomes collected included perioperative surgical management, adverse events, and bleeding events. Twenty publications were included; 72 procedures were reported. Twenty-two orthopedic and 34 other major procedures were specifically described. FVIII replacement was used to manage 66 procedures perioperatively, and 25 procedures were managed in conjunction with antifibrinolytics. Fifteen procedures resulted in a bleeding event, and one individual experienced a thrombotic event. No deaths were reported. This review provides a consolidated narrative of the currently reported experiences of emicizumab-treated people with hemophilia A without FVIII inhibitors undergoing major surgery, helping to support the future management decisions of emicizumab-treated people with hemophilia A during surgery.
无因子VIII抑制剂的A型血友病患者应用emicizumab进行大手术的文献综述
A型血友病患者全部或部分缺乏因子(F)VIII,导致自发性和/或外伤性出血进入关节、肌肉和软组织。血友病a患者可能需要大手术来恢复关节活动能力或治疗常见合并症的症状。围手术期建议进行额外的因子置换;目前缺乏关于半珠单抗治疗的A型血友病患者在大手术期间的经验的整理信息。为了提供emicizumab在无FVIII抑制剂的a型血友病患者接受大手术的经验的综合叙事性总结,使用PubMed/MEDLINE进行了全面的文献检索(截止日期:2024年3月31日);人工检索2016-2024年适用大会的摘要图书。所有年龄的A型血友病患者和严重程度的A型血友病患者的原始数据均被纳入研究,这些血友病患者未使用emicizumab预防FVIII抑制剂,并接受了大手术。收集的结果包括围手术期手术处理、不良事件和出血事件。其中包括20份出版物;报告了72例手术。对22例骨科手术和34例其他主要手术进行了详细描述。FVIII置换用于66例围手术期手术,其中25例与抗纤溶药物联合治疗。15例手术导致出血事件,1例发生血栓事件。没有死亡报告。本综述对目前报道的未使用FVIII抑制剂的半单胞单抗治疗的a型血友病患者接受大手术的经验进行了综合叙述,有助于支持半单胞单抗治疗的a型血友病患者在手术期间的未来管理决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
13.00%
发文量
212
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信